Ann: Update - Consolidation/Split - OSX, page-16

  1. 9,345 Posts.
    lightbulb Created with Sketch. 8005
    There is some pathetic drivel about things having changed since the consolidation in the entitlement offer. A subterfuge no doubt, and suspect this was somewhat planned all along with the consolidation. They prematurely announced the $10 mill from CellHeal in July 2023 and have clearly cocked that deal up ever since.

    It was a always call option equivalent buy for me late in its price cycle (post 2023 raise) on the Chinese/Singapore deals that that they've clearly stalled on - no doubt their potential partners negotiating hard knowing their funding woes. This CEO doesn't have a clue on capital mkts and the Board should be strung up for dereliction of duty in not raising capital when the stock price was $4+ twice in 2022. How can they not get a decent $3 million loan/grant now on the back of Singpaore A*Star collaboration, or alleged pending Chinese partnerships defeats me.

    I am taking a rib punch, but feel for long-term shareholders. This comedic Board and executive team have at last half yearly, raised $29,470,027 in capital since IPO from shareholders and had accumulated losses of $13,879,948 for a closing mkt cap of less than $4 million, after promising so much.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.1¢
Change
0.000(0.00%)
Mkt cap ! $2.609M
Open High Low Value Volume
1.0¢ 1.1¢ 1.0¢ $29.95K 2.862M

Buyers (Bids)

No. Vol. Price($)
14 2353146 1.0¢
 

Sellers (Offers)

Price($) Vol. No.
1.1¢ 2096673 5
View Market Depth
Last trade - 16.10pm 08/08/2025 (20 minute delay) ?
OSX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.